Description

Repligen Corporation: From SoloVPE Upgrades to Custom Resins—What’s Powering the Growth Momentum?

Repligen Corporation closed 2025 with strong operational momentum, delivering fourth-quarter revenue of $198 million and full-year revenue of $738 million while exceeding the upper end of prior guidance for both revenue and adjusted operating income. Organic revenue growth reached 14% in the fourth quarter and 16% for the full year on a reported and non-COVID organic basis. Growth was supported by broad-based strength across multiple product franchises, particularly Proteins and Process Analytics, which expanded more than 30% during the quarter. Chromatography also posted more than 25% growth, while Filtration grew at a high single-digit rate. Management highlighted the diversity of the portfolio as a key factor enabling performance above overall bioprocessing market growth, supported by strong demand from biopharma customers across all geographic regions. Operationally, Repligen Corporation improved profitability while continuing to invest in infrastructure and strategic initiatives. Gross margin reached 52.